Borst
Recurrent and/or metastatic breast cancer with low HER-2 expression
A phase I/II multi-centre study of AZD8931 in combination with weekly paclitaxel to assess the safety, tolerability, pharmacokinetics and efficacy in patients with advanced solid tumors and in a selected population with low HER2-expressing locally recurrent and/or metastatic breast cancer. ( Thyme )
- Study Phase I (solid) -II (breast)
- Selection criteria
Eearly stage breast cancer at high risk of recurrence
A randomized, double blind, placebo controlled multicenter phase 3 study of denosumab as adjuvant treatment for women with early stage breast cancer at high risk of recurrence. (D-Care)
-
Study phase III
Locally advanced or metastatic
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
- Study phase III
- Selection criteria
Locally advanced or metastatic
A randomised Double-Blind, Placebo-Controlled study of Everolimus in combination with exemestane in the treatment of postmenopauzal women with estrogen receptor positive locally advanced or metastatic breast cancer who are refractory to Letrozole or Anastrozole
- Study Phase III
- Selection criteria
Adjuvant or metastatic
Rhea study: Phase II study of Herceptin, alone or in combination with a taxane, as a first-line treatment for patients with metastatic breast cancer, who have relapsed after receiving Herceptin in the adjuvant setting for HER2 positive early breast cancer.
- Study Phase II
ERB2+ primary breast cancer
A randomised, multi-centre, open-label, phase III study of adjuvant
lapatinib, trastuzumab, their sequence and their combination in patients
with HER2/ErbB2 positive primary breast cancer.
- Study Phase II
- Selection criteria
Metastatic breast cancer, first line
A Randomized, open-label, Phase 3 Study of Taxane based chemotherapy with Lapatinib or Trastuzumab as first-line therapy for women with HER2/Neu positive breast cancer.
- Study Phase III
- Selection criteria
Hormone receptor positive breast cancer
A phase III trial evaluating the role of continuous Letrozole vs Intermittenet Letrozole following 4 to 6 years of prior adjuvant endocrine therapy of postmenopausal women with hormone-receptore positive, node positive early stage breast cancer.
- Study Phase III
- Selection criteria
Early breast cancer
Comparison of IL-6 and other serum inflammatory cytokines in postmenopausal early breast cancer patients treated with an AI and developing an arthalgia syndrome, arthalgia G2 or G3 with patients experiencing no complaints of arthalgia.
Advanced disease
A randomized discontinuation study of Brivanib alaninate (BMS-582664) versus Placebo in Subjets with advanced tumors.
- Study Phase II
- Selection criteria